Immunological monitoring of azathioprine treatment in multiple sclerosis patients

Journal of Neurology

Volumn 244, Issue 3, 1997, Pages 167-174

  Salmaggi, Andrea ^a   Corsini, Elena ^a   La Mantia, Loredana ^a   Dufour, Anna ^a   Eoli, Marica ^a   Milanese, Clara ^a   Nespolo, Angelo ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Azathioprine; Clinical efficacy; Cytokines; Lymphocyte subsets; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CD45 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MONITORING; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AZATHIOPRINE; B-LYMPHOCYTES; CYTOKINES; DRUG MONITORING; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, NATURAL; MALE; MULTIPLE SCLEROSIS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY;

EID: 0031038535     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050068     Document Type: Article

References (41)

1. Adachi K, Kumamoto T, Araki S (1989) Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet I : 559-560
2. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J (1988) Increased production of Interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78 : 318-323
3. Brinkman CJJ, Nillesen WM, Hommes OR (1983) T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effects of cyclophosphamide. Cinical Immunol Immunopathol 29 : 341-348
4. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37 : 424-435
5. Caputo D, Zaffaroni M, Ghezzi A, Cazzullo CL (1987) Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis. Acta Neurol Scand 75 : 84-86
6. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE (1992) Tumor necrosis factor alfa production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 3 : 523-531
7. Cseuz R, Panayi GS (1990) The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis. Br J Rheumatol 29 : 358-362
8. Dixon JS, Bird HA, Sitton MG (1983) Serum biochemistry in relation to the action of azathioprine in rheumatoid arthritis. Agents Actions 13 : 373-379
9. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R, Peterson M (1995) Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 37 : 55-62
10. Frei K, Fredrikson S, Fontana A, Link H (1991) Interleukin 6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 43 : 147-153
11. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC (1989) Human biological response modification by interferon in the absence of measurable serum concentration: a comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst 81 : 1061-1068
12. Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL (1991) Immunological effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 32 : 149-158
13. Hartung HP, Michels M, Reiners K, Seeldrayers P. Archelos JJ, Toyka KV (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 43 : 2331-2335
14. Hercend T, Schmidt RE (1988) Characteristics and uses of natural killer cells. Immunol Today 9 : 291-301
15. IFN-β Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 : 655-661
16. Jander S, Heidenreich F, Stoll G (1993) Serum and CSF levels of soluble Intercellular Adhesion Molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43 : 1809-1813
17. Katz P (1983) Therapy for immunologic disease. Postgrad Med 74 : 353-360
18. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33 : 1444-1445
19. Lisak RP (1988) Overview of the rationale for immunomodulating therapies in multiple sclerosis. Neurology 38 [Suppl 2] : 5-8
20. Matsumoto K, Sekita K, Ochiai T, Takagi A. Takada K, Furuya T, Kurosawa Y, Saito Y, Teshima R, Suzuki K (1990) Evaluation of immunotoxicity testings using azathioprine-treated rats: the International Collaborative Immunotoxicity Study (Azathioprine). Eisei Shikenjo Hokoku 108 : 34-39
21. Moreau JF, Ythier A, Soulillou JP (1981) Natural killer activity in kidney allograft recipients. Transplant Proc 13 : 1610-1613
22. Morimoto C, Hafler DA, Weiner HL, Letvin NL, Hagan M, Daley J, Schlossman SF (1987) Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis: analysis with anti-2H4 monoclonal antibody. N Engl J Med 316 : 67-72
23. Munschauer FE, Hatrich LA, Stewart CC, Jacobs L (1995) Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 62 : 177-181
24. Oger JJF, Antel JP, Kuo HH, Arnason BGW (1982) Influence of azathioprine (Imuran) on in vitro immune function in multiple sclerosis. Ann Neurol 11 : 177-181
25. Panitch HS (1994) Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36 [Suppl] : 25-28
26. Pedersen BK, Beyer JM, Rasmussen A, Klarlund K, Horslev-Petersen K, Pedersen BN. Helin P (1984) Azathioprine as single drug in the treatment of rheumatoid arthritis induces complete suppression of natural killer cell activity. Acta Pathol Microbiol Immunol Scand 92 : 221-225
27. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic critiera for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 : 227-231
28. Posey WC, Nelson HS, Branch B, Pearlman DS (1978) The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 62 : 340-348
29. Rieckmann P, Martin S, Weichselbraun I, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: sICAM-1 is an indicator for relapse. Neurology 44 : 2367-2372
30. Salmaggi A, La Mantia L, Milanese C, Bianchi G, Eoli M, Campi A, Nespolo A (1989) CSF T-cell subsets in multiple sclerosis: relationship to cerebrospinal fluid myelin basic protein and clinical activity. J Neurol 236 : 336-339
31. Salmaggi A, Milanese C, Eoli M, La Mantia L, Nespolo A, Dufour A (1994) Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients. Int J Neurosci 76 : 305-312
32. Sanders ME, Makgoba MW, Shaw S (1988) Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol Today 9 : 7-17
33. Selmaj K, Raine CS, Canella B, Brosnan CF (1991) Identification of lymphotoxin and tumour necrosis factor in multiple sclerosis lesions. J Clin Invest 87 : 949-95
34. Shih WWH, Ellison GW, Myers LW, Durkos-Smith D, Fahey JL (1982) Locus of selective depression on human natural killer cells by azathioprine. Clin Immunol Immunopathol 23 : 672-681
35. Spina CA (1984) Azathioprine as an immune modulating drug: clinical applications. Clin Immunol Allerg 4 : 415-446
36. Ten Berge RJ, Schellekens PT, Surachno S (1982) A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients. Clin Immunol Immunopathol 24 : 33-46
37. Trotter JL, Rodey GE, Gebel HM (1982) Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 92 : 167-174
38. Vervliet G, Claeys H, Van Haver H, Carton H, Vermylen C, Meulepas E, Billiau A (1983) Interferon production and natural killer (NK) cell activity in leucocyte cultures from multiple sclerosis patients. J Neurol Sci 60 : 137-150
39. Vitale M, Neri LM, Comani S, Falceri E, Rizzoli R, Rana R, Papa S (1989) Natural killer function in flow cytometry. J Immunol Methods 121 : 115-120
40. Webb DR, Winkelstein A (1980) Immunosuppression and immunopotentiation. In: Fudemberg HH, Stites DP, Caldwell JL, Wells JV (eds) Basic and clinical immunology. Lunge, Los Altos, Calif, pp 313-326
41. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RAC, McPherson K, Merlin J, Milanese C (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338 : 1051-1055